CSTL (Castle Biosciences) YoY EBITDA Growth : 396.38% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Castle Biosciences YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Castle Biosciences's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 396.38%.

Castle Biosciences's EBITDA per Share for the three months ended in Sep. 2024 was $0.41.

Castle Biosciences YoY EBITDA Growth Historical Data

The historical data trend for Castle Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences YoY EBITDA Growth Chart

Castle Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

436.26

-131.59

-288.27

-53.78

24.97

Castle Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY EBITDA Growth	Get a 7-Day Free Trial															79.03	103.73	103.14	168.03	396.38

Castle Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Castle Biosciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-1.68	-	-2.239)	/	\| -2.239 \|
=	24.97 %

Castle Biosciences's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2024 )
=	(EBITDA per Share (Q: Sep. 2024 )	-	EBITDA per Share (Q: Sep. 2023 ))	/	\| EBITDA per Share (Q: Sep. 2023 )) \|
=	(0.409	-	-0.138)	/	\| -0.138 \|
=	396.38 %

Castle Biosciences YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Castle Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 South Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546

Website

https://www.castlebiosciences.com

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Executives

Derek J Maetzold	director, 10 percent owner, officer: Pres. & Chief Exec. Officer	820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Kristen M Oelschlager	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Frank Stokes	officer: Chief Financial Officer	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Ellen Goldberg	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple	director	C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tobin W Juvenal	officer: Chief Commercial Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff	director, 10 percent owner	C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii	director, 10 percent owner	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p.	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203